Mediterranean Diet and Intermittent Fasting Show Promise Against Common Fatty Liver Disease

A team of researchers at the University of Rovira i Virgili in Spain has gone back through the existing evidence on diet and fatty liver disease, and what they found points in a fairly consistent direction. Pulling together 13 earlier trials and studies, covering 926 people in total, they asked which eating patterns seemed to help those living with metabolic dysfunction-associated steatotic liver disease, or MASLD. Every participant in the reviewed work had the condition.

MASLD is common. It affects roughly one in three people worldwide, and it develops when too much fat accumulates in the liver. From there it can lead to inflammation, fibrosis and cancer, and it is closely tied to type 2 diabetes and obesity.

Across the range of dietary approaches the trials examined, the Mediterranean diet stood out for its health benefits. Intermittent fasting also made a notable difference on several key markers. The researchers report that these diets reduced several signs of MASLD in the liver. In their words, Mediterranean and fasting-based strategies may reduce body weight, improve glycemic control and lower inflammation, with potential benefits for liver function.

The Mediterranean diet is built around fruits, vegetables, whole grains, nuts, olive oil, fish and poultry, while keeping sugar, red meat and processed foods to a minimum. It takes its name from the region where it originated, particularly countries such as Greece and Italy, and it has been followed for thousands of years. It has already been linked to a host of benefits, including longer life and lower cancer risk, and earlier work associated it with reduced severity of fatty liver disease.

There is an important limit on what this review can say. Although all the included studies involved people with MASLD, the disease was not their primary focus. The Spanish team is connecting dots: they look at how biomarkers such as blood sugar control and inflammation levels might relate to MASLD outcomes. The liver benefits are therefore inferred from those markers rather than measured directly. The authors acknowledge that data on liver function outcomes were limited, though they describe the results as an early indication of promise for Mediterranean-based interventions.

In theory, the improvements seen should lessen the severity of MASLD or stop it from developing at all. But the source is careful not to assume direct cause and effect, since so many variables are involved in how people eat and how their bodies respond. The researchers describe MASLD as a complex condition with many contributing factors, including nutrition and immune-metabolic health, which is why they think studying dietary patterns alongside immuno-metabolism could matter for managing it.

What the authors ask for next is longer-term research: studies that follow disease progression over time, confirm the effects and the mechanisms behind them, and establish the safety of these approaches in people with MASLD. Only then, they say, can the protocols be optimized. The review is published in the journal Nutrients.